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Acceptable palatability is paramount for paediatric formulations.
A survey of over 800 paediatricians showed that unpleasant taste of
medication is a key barrier to compliance for 90.8% of patients with
acute illness and 83.9% of patients with chronic illness [1]. Compliance
rates in children have been found to range from 11 to 93%, with major
factors attributed to formulation and palatability [2]. Palatability is
largely dictated by taste and this is a concern as a signiﬁcant number
of active pharmaceutical ingredients (APIs) on themarket and in devel-
opment have aversive taste. This is not considered to be a key issue
when developing oral dose forms for adults who can swallow tablets
since such products can be ﬁlm or sugar-coated, thereby masking the
taste of the API. In the paediatric population the issue is accentuated
by dysphagia, leading to an increased use of oral dosage forms such as
liquids, (oro-) dispersible and chewable tablets where taste masking
becomes a greater challenge. In addition, differences in taste perception,
sensitivity and tolerance between adults and children make taste
assessment and development of palatable paediatric medications more
complex.
The paediatric population represents a diverse group of patients,
exhibiting differences in biological and physiological attributes com-
pared to adults. Indeed, children are notmerelyminiature adults because
sensory systemsmature postnatally and their responses to certain tastes
differ markedly from adults. Amongst these differences are heightened
preferences for sweet-tasting and greater rejection of bitter-tasting
foods [3]. In addition, APIs and excipients are metabolized differently
by children of different ages compared to adults [4]. Therefore the use
of certain excipientsmay not be appropriate or the levels will be restrict-
ed, which further complicates excipient selection.
Indeed, when designing an age-appropriate paediatric medicinal
product, the excipients used should be selected using a beneﬁt risk ap-
proach, encompassing all aspects of the proposed excipients in parallel,
including:
• physico-chemical properties (stability, solubility, compatibility etc.)
• purity (identiﬁcation and quantiﬁcation of impurities)
• toxicity (quality and relevance of data)
• acceptable daily intake (ADI)
• tolerability (risk of allergies/sensitization, cariogenicity, gastrointesti-
nal osmotic effects and metabolic fate, caloric contribution)
• the patient's age
• the patient's susceptibility (diabetic patients, patients with allergies
etc.)
• dosage regimen/exposure (quantities, duration and frequency of
administration)
• possible cumulative effect with excipients in concomitant medica-
tions
• regulatory status.
Acceptability is an overall ability of the patient and caregiver
(deﬁned as ‘user’) to use amedicinal product as intended (or authorised).
Acceptability of amedicinal product is likely to have a signiﬁcant impact
on the patient's adherence and consequently on the safety and efﬁcacy
of the product.Acceptability is driven by the characteristics of the user (age, ability,
disease type and state) and by the characteristics of amedicinal product
such as:
• palatability
• swallowability (volume/size and shape, integrity of dosage form,
e.g. functional coating)
• complexity of manipulation if required
• the required dose e.g. the dosing volume, number of tablets etc.
• the required dosing frequency and duration treatment
• the selected administration device
• the primary and secondary container closure system
• the actual mode of administration.
Palatability is one of themain elements of the patient acceptance of a
medicinal product. It is deﬁned as the overall appreciation of an (often
oral) medicine by organoleptic properties such as smell, taste, aftertaste
and texture (i.e.mouthfeel), and possibly also vision and sound. It is de-
termined by the characteristics of the components (API and excipients)
and the way the API is formulated. Palatability is relevant for other
routes of administration e.g. buccal, nasal, inhalation. Thus not only
should a medicinal product not taste and smell (especially the aroma
on ﬁrst opening and during consumption) unpleasant, it should have
acceptable mouthfeel (viscosity, grittiness) and appearance (visual as-
pect, size and shape, packaging). Thus palatability and indeed accept-
ability are key considerations when deﬁning the target product proﬁle.
The importance of acceptable palatability has been recognised by
regulatory authorities, including the European Medicines Evaluation
Agency (EMA) [5]. The French regulatory authorities (Afssaps) launched
a study designed to determine the acceptability of oral liquid originator
and generic antibiotics prescribed to ambulatory children [6]. The dis-
parity in the acceptability of the different antibiotics prescribed, even
for the same drug has been conﬁrmed by Wollner et al. [7].
Moreover within the requirements of the European Union's Paediat-
ric Regulation [8], paediatric investigation plan (PIP) guidelines state
that the proposed studies of particular relevance to the development
of paediatric products may include:
– Taste masking or palatability.
– Compatibility with administration systems e.g.medical devices.
– Compatibility and stability in the presence of relevant common
foods and drinks.
As stated above, the majority of API's have an unpleasant taste. The
pragmatic approach often taken by patients and carers to facilitate dos-
ing is to dilute or obscure the taste of a medicinal product by mixing or
sprinkling it in food/beverages. However, there are risks associatedwith
using this approach. For example the entire dose of the medicinal prod-
uct may not be consumed especially if the volume or quantity of food/
beverage is too large or taste not appropriately masked. In addition,
this approach may result in the child being put off the food/beverage
used, which could be a particular issue for very young children and
babies where milk is the main food source. Hence mixing with food or
beverage should not be the primary means of taste masking a formula-
tion. However, should mixing with food/beverages be recommended,
appropriate in vitro compatibility testing should be conducted during
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tion instructions for users in the summary of product characteristics
(SPC). The subject of taste masking APIs and medicinal products
via pharmaceutical development means has been discussed by many
authors in the past decade [9–11].
The aim of this review is to provide an overview of different
approaches and pharmaceutical platform technologies that may be
utilised for the taste masking of APIs in paediatric oral dosage forms,
with a focus on excipients used together with the provision of examples
of somemarketed products. In addition, the tolerability of tastemasking
excipients will be discussed. Although there is a clear need for robust
and reliable in vitro and in vivo taste assessment methodologies, this
topic is out of scope of the current review.
The aim of taste masking techniques is to obscure the aversive taste
of an API or formulation, or to prevent interactions of the dissolved API
with the taste receptors in the mouth and throat. An overview of taste
masking techniques is presented in Fig. 1.
2. Bitter blockers and taste modiﬁers
Although currently not widely precedented, some emerging tech-
nologies are discussed ﬁrst as they interfere directly with the taste
receptor or taste transduction mechanism. Bitter blockers work by bio-
chemically interfering with the taste transduction frommouth to brain.
Taste transduction is a complex process and different mechanisms for
preventing bitter taste have been proposed depending on where the
taste signal cascade is blocked.
2.1. Bitter receptor antagonists
At least 25 different bitter taste receptors have been discovered to
date. These receptors are genetically extremely diverse, which explains
different sensitivity to bitter tastes within the population. Taste genetics
play an important role in a child's acceptance of oral liquid medications
and experience with solid oral formulations. For example, childrenwith
bitter-sensitive TAS2R38 genotypes prefer sweeter formulations and
are more likely to have had experience with (less bitter tasting) solid
dosage forms [12].
Bitter receptor antagonists bind competitively to a speciﬁc bitter
receptor site, thereby blocking the release of a G-protein, gustducin
[13]. These antagonists are often tasteless compounds that are close
structural analogues of known bitter compounds, hence binding to the
same receptor [14].
Bitterness inhibition at the receptor level can only be achieved suc-
cessfully if the bitter API molecule and the bitter blocker bind to exactly
the same receptor. It is normally not knownwhich bitter receptor anAPIAPI
receptor
TASTE
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Fig. 1. Overview of tastemolecule interacts with, and likewise the receptor interaction of bitter
blockers is often not fully understood. In practice, the selection of bitter
receptor antagonists is therefore usually conductedwith limited success
via a ‘trial and error’ approach.
2.2. Taste transduction cascade blockers
Broad bitterness inhibition, with potential as a platform technology,
is most likely to be achievable if a late stage in the taste transduction
pathway can be blocked. As shown in Fig. 2 [15], certain ‘bitter blocking’
molecules can interact with taste transduction steps beyond the recep-
tor interaction (1). Potential interactions can occur during the following
steps: at the receptor–G protein (gustducin) interaction (2), at the
activation of G protein (3), at the G protein effector (phospholipase
C) interaction (4), at the generation of the second messenger (cAMP)
(5), and at the ion channel activation step (6).
The ion channel, Transient Receptor Potential cation channel sub-
familyMmember 5 (TRPM5), is an essential component of this cascade.
By controlling the activity of TRPM5 it is thought that unwanted bitter
tastes can be mitigated or even abolished, or desirable sweet and
umami ﬂavours can be enhanced. Compounds that speciﬁcally inhibit
or enhance TRPM5 activity are currently under development as bitter
blockers for both pharmaceuticals and foods such as processed soy
and cocoa; however they are not expected to be commercialized for
several years [16].
2.3. Gaps in current knowledge and technology limitations
The principle of bitter blockers is relatively new to taste masking of
pharmaceutical dosage forms, and there is limited precedence of bitter
blockers and other taste modiﬁers in marketed pharmaceutical prod-
ucts (see Table 1). Apart from sodium ions, no precedence for their
use in paediatric products has been identiﬁed.
The transduction mechanism underlying bitter taste perception and
the exactmechanism of action of bitter blockers are not yet fully under-
stood. Therefore the selection of bitter blockers for taste masking
purposes is often carried out by an empirical approach, with a limited
likelihood of success. With progress in understanding the molecular
mechanisms underlying bitter taste perception and with the help of re-
combinant DNA technology it may in the future be possible to predict
the efﬁcacy of bitter blockers for a drug of interest, and to determine
the structure activity relationship (SAR) between taste modiﬁers and
the proteins with which they interact [17]. An increased understanding
of this relationship may in the future help in selecting the most appro-
priate bitter blocker for speciﬁc applications. However, the use of bitter
blockers in taste masking applications is likely to remain challengingB) Obscuration of taste
Viscosity
Sweeteners/Flavouring Agents
C) Modification of API
Solubility (salt, pH)
Prodrug
A) Numbing the taste buds
Taste ‘Blockade’(Research)
masking methods.
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Second 
messengerEnzyme
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Fig. 2. Taste transduction (derived from McGregor, 2007 [15]).
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pathways involved in bitterness perception.
Due to their mechanism of action, bitter blockers will require
administration prior to dosing of a bitter medicinal product, resulting
in challenges related to compliance (i.e. administration of additional
formulation to paediatric patients) and increased cost. It is also not un-
derstood whether bitter blockers are able to remove or at least reduce
the aftertaste caused by bitter APIs. Aftertaste is a major factor reducing
compliance as it can often last for several hours following administra-
tion of a medicinal product.
Sensitivity to bitterness is age-related and is known to be different in
adults and children. Methodologies to study the efﬁcacy of bitter
blockers in reducing the bitter taste of medicinal products need to be
developed in paediatric and adult panels. Although there is a relatively
large patent literature on bitter blockers and other taste masking tech-
nologies [9], few published studies investigated the efﬁcacy of blockers
in humans; and none in children, except for sodium chloride [18].
The safety and toxicology of bitter blockers in humans, and in partic-
ular in children, need to be investigated. Bitter receptors are not only
found on the tongue, they also exist in the throat and lungs [19], and
little is known about the impact of their action on these receptors.
Due to their mechanism of action, taste modiﬁers may not be regarded
as ‘inactive’ ingredients in pharmaceutical products, which in turn may
have regulatory implications. Indeed, the regulatory status of most taste
modiﬁers currently limits their use in pharmaceuticals.
In summary, broad bitterness inhibition,with potential as a platform
technology for paediatric dosage forms, is difﬁcult to achieve and
requires blocking of the taste transduction process beyond the receptor
level. Even if suitable molecules were to be identiﬁed, their use in phar-
maceuticals, and especially in paediatric formulations, is likely to be lim-
ited due to toxicological, safety and regulatory concerns.
Some of the potential beneﬁts and limitations of bitter blockers are
summarised in Table 2.3. Sweeteners and ﬂavouring systems
Sensory based taste masking approaches have been commonly used
for decades as it is the most intuitive approach to obscure aversive API
tastes such as bitterness, excessive saltiness, astringency, and metallic
taste. However as any compounds dissolved in the saliva will interact
with the taste receptors and elicit a response, this approach does not
workwell for highly aversive APIs and for APIswith an intense lingering
aftertaste. Moreover it is very difﬁcult to predict whether this approach
will actually work at all (unless conclusive taste data for API in water is
available), and it is often a ‘trial-and-error’ approach (requiring several
taste tests) to seewhich combinations and levels ofﬂavours/sweetenersmay work. Nevertheless, the concept is versatile and can be applied to
liquid or solid formulations that are applicable to younger patients
(solutions/suspensions, soluble or dispersible tablets, oral wafers) or
school age children (chewable tablets, orodispersible tablets (ODTs)).
The use of ﬂavours and/or sweeteners can be very effective (e.g.Diovan®,
valsartan solution); however this is very much a non-platform technol-
ogy and needs to be optimised on a case by case basis.
The usual taste masking development sequence, by which sweeten-
er and ﬂavouring agent compatibility with other excipients, stability
and importantly tolerability needs to be taken in account, is to develop
a sweetener blend, and then to add/complement with supporting
ﬂavours for aroma and taste [35].3.1. Sweeteners
There are 2 main categories of sweeteners: bulk and intense sweet-
eners, as listed in Table 3. The former provides body and texture to the
product (sucrose being the ‘syrup’ reference for pharmaceuticals) and
the latter provides intense sweet taste at very low concentrations. The
sweeteners used inmedicinal products can be either artiﬁcial or natural.
It should be noted that not all sweeteners are globally acceptable
from a regulatory perspective which limits the number of sweeteners
that can be consideredwhen developing a global commercial paediatric
product. For example, cyclamates are not permitted in USA but are in
Canada and in the EU, and neotame has been approved as a food addi-
tive in Australia since August 2001 and in the USA since July 2002, but
has only been approved in the EU since 2010.
It is difﬁcult to determine the prevalence and extent of sweeteners
used. Itmay be considered that newer sweeteners and those not includ-
ed in the US Food and Drug Administration (FDA) list of inactive ingre-
dients [36] (e.g. alitame, neohesperidin dihydrochalcone, steviosides
and thaumatin), are less likely to be used in pharmaceutical products
than those included in the FDA list.
Different sweeteners have advantages and disadvantages in terms of
sensory qualities (taste, texture) and processability (temperature and
pH stability). Fig. 3 represents sweetness intensity temporal proﬁles
of acesulfame potassium (Ace-K), saccharin aspartame, sucralose and
neotame versus sucrose ranging from early-middle to middle-late
onset of sweetness [37]. They provide a palette of sweetness choice to
match the taste proﬁles of APIs. Compounds such as glucose and sorbitol
have an early onset sweetness whilst that for thaumatin for example is
late onset. A combination of sweetenersmay be used in order to provide
sufﬁcient sweetness and intensity as a function of time to mask the
unpleasant taste of an API in a particular oral dosage form, although
concentrations required will depend upon the dose/strength of the
product and properties of the drug (physical state, solubility). Indeed
Table 1
Examples of bitter blockers and other taste modiﬁers.
Bitter blocker/taste modiﬁer Mechanism Applications Limitations Regulatory status Precedence in
pharmaceuticals
Adenosine 5′-monophosphate (AMP)
• Nucleotide found in RNA
• Natural constituent of many foods,
including breast milk
• May bind to bitter-responsive taste
receptors or interfere with receptor-G protein
coupling to serve as naturally
occurring taste modiﬁer [20].
• Reduces the bitter taste of potassium in
low-sodium foods containing KCl. Reduces
bitterness of selected drugs [21].
• Reduces bitter aftertaste of artiﬁcial
sweeteners, e.g. saccharin [17].
• Likely to only block certain types of
bitterness due to interaction with speciﬁc
bitter taste receptors.
• Savoury (umami) taste may limit its use in
pharmaceutical applications.
• GRAS status for use in foods, beverages and
oral pharmaceutical dosage forms since 2004
[22].
• No precedence in
pharmaceuticals
identiﬁed.
Use in foods only.
Sodium ions • Sodium ions may act by shielding receptor
proteins from bitter compounds, modulating
ion channels or pumps, stabilising the cell
membrane or interfering with second
messenger systems after entering receptor
cells [21].
• In adults, sodium salts can suppress the
bitter taste of some bitter compounds [4,21]
• Dependent on counter ion. • Used in
pharmaceuticals
and foods.
Neohesperidin dihydrochalcone (E959)
• Synthesised by hydrogenation of
neohesperidin, a bitter ﬂavonoid occurring
naturally in Seville oranges (Citrus
aurantium). (Also see Section 3.1).
• Mechanism of action for bitterness
suppression is not known, but may be related
to the sweetener properties of the molecule
[23,24].
Low-calorie intense sweetener, ﬂavour
modiﬁer and bitterness suppressor.
Optimum neohesperidin dihydrochalcone
concentrations are
API-dependent and need to be determined
on a case-by-case basis.
• GRAS listed
• Authorised sweetener in the European
Parliament and Council Directive 94/35/EC of
30 June 1994 on Sweeteners for Use in
Foodstuffs
• Authorised ﬂavour enhancer in certain
applications under the European
Parliament and Council Directive 95/2/EC on
Additives Other than Colours and Sweeteners.
• ADI of 0–5 mg/kg body-weight (Europe)
•Monographs in Ph. Eur (2001) and BP [23,25].
• No precedence in
pharmaceuticals
identiﬁed.
Thaumatin (E957)
•Mixture of ﬁve proteins isolated from the
fruit of the African plant Thaumatococcus
daniellii.
• The tertiary structure of the molecule may
enable it to interact with bitter taste receptors.
• Used as a sweetening agent and ﬂavour
enhancer in food applications. It is claimed
that thaumatin is effective at masking
bitterness and off notes in foods, supplements
and pharmaceuticals.
• Used in antibiotics, analgesics, antacids,
cough syrups, common cold remedies,
medicated gums, vitamin preparations and
oral hygiene products [26].
• Long (up to onehour) liquorice-like aftertast
• Optimum thaumatin concentrations are
API-dependent and need to be
determined on a case-by-case basis.
• Accepted for use in food products as a
sweetener or ﬂavour modiﬁer in a number of
areas including EU and Australia.
• In Europe, because of its lack of toxicity, an
ADI of ‘not speciﬁed’ has been set.
• GRAS listed and included in nonparenteral
medicines licensed in the UK.
• No precedence in
pharmaceuticals
identiﬁed.
Flavonones and structurally related
compounds
• Eriodictyol, homoeriodictyol, its sodium
salt and sterubin are ﬂavanones extracted
from Eriodictyon californicum, a plant native
to N. America.
• Flavanones only partially block bitter
reception. They may not compete with bitter
molecules on taste receptors but bind to a
second site common to all bitter receptors
[27].
• Homoeriodictyol sodium salt shows potent
bitter-masking activity, reducing the
bitterness of salicin, amarogentin,
paracetamol and quinine [27].
• No information found. • No precedence in
pharmaceuticals
identiﬁed.
Derivatives of cinnamic acid
• Ferulic acid is an organic compound that
is found in plant cell walls
Caffeic acid is a key intermediate in the
biosynthesis of lignin.
• Mechanism unknown. • Caffeic acid, ferulic acid and their salts are
patented as bitterness inhibitors in foods, to
mask the bitter aftertaste of the artiﬁcial
sweeteners acesulfame potassium and
saccharin [28].
• No information found. • No precedence in
pharmaceuticals
identiﬁed.
Miraculin
• Glycoprotein extracted from miracle
berry, the fruit of the West African bush
Synsepalum dulciﬁcum.
• No taste of its own but interacts with the
taste receptors in themouth and allows acidic
foods to taste sweet for up to 2 hours [29].
• The exactmechanism is unknown.Miraculin
may distort the shape of sweetness receptors
so that they become responsive to sour
instead of sweet molecules [30].
• Miracle Fruit™ supplement has been
reported to improve
chemotherapy-associated taste
changes [31].
• Currently no standardised plant extract
available. No secure source of material. No
chemical synthesis at commercial scale.
• Rapid degradation following harvest of
berries — freeze drying required to enhance
stability.
• No toxicological data available.
Impact on sour taste only [32,33].
• No regulatory approval for use in
pharmaceuticals or foods.
• No precedence in
pharmaceuticals
identiﬁed.
Lipoproteins
• Composed of phosphatidic acid and
beta-lactoglobulin.
• Canmask target sites for bitter substances on
the taste receptor membrane without
affecting responses to sweet, salty or acidic
tastes [34].
• Phosphorylated amino acids have been
found to inhibit unpleasant taste of ibuprofen,
paracetamol, dextromethorphane HCl and
other drugs [34].
• No information found. • No precedence in
pharmaceuticals
identiﬁed.
GRAS — generally regarded as safe, ADI — acceptable daily intake.
18
J.W
alsh
etal./A
dvanced
D
rug
D
elivery
Review
s
73
(2014)
14
–33e.
Table 2
Summary of beneﬁts and limitations of bitter blockers.
Beneﬁts Limitations
Potentially more effective at controlling bitterness than conventional taste masking
approaches such as use of sweetener and ﬂavours.
Understanding of bitter blocker mechanism is currently limited. Selection often based on
‘trial and error’ approach.
Can overcome limitations of other technologies such as bioequivalence issues with
coatings.
Limited regulatory acceptability for use in pharmaceuticals.
Useful for bitter APIs that are delivered buccally or sublingually. For these drugs suitable
taste masking approaches are currently limited to use of sweeteners and ﬂavours.
Safety and toxicology in adult and paediatric population largely unknown.
Effective at very low concentration, hence suitable for dosage forms where high levels of
excipients are unsuitable, e.g. oral ﬁlms.
May require administration of the bitter blocker prior to unpleasant tasting medicine—
administration of two separate dosage forms will impact compliance and increase cost.
API — active pharmaceutical ingredient.
19J. Walsh et al. / Advanced Drug Delivery Reviews 73 (2014) 14–33binary mixtures of sweeteners are frequently used synergistically, a
typical mixture being aspartame–acesulfame K (E962) which has a
synergistic sweetness which is 350 more than sugar alone [24,38].
3.2. Flavours
Natural and artiﬁcial ﬂavours are available. Naturalﬂavours have the
advantage of better palatability over artiﬁcial ﬂavours which are easier
to characterise and more chemically stable [39] and therefore likely to
overcome ﬂavouring agents' batch to batch variability and potential
changes in taste with time. This highlights additional issues such as
the requirement to meet speciﬁcation throughout product shelf life
and the challenge of selection of methodologies (in vivo-human panels
or in vitro-taste sensors) to evaluate taste stability over time. Further-
more, ﬂavours are often complex mixtures and exact composition is
usually not known,which can complicate the assessment of compatibil-
ity with other components within a formulation. Flavours may be avail-
able as liquids, some of which contain ethanol and/or propylene glycol
usually in very small quantities which may not raise concern, or solidsTable 3
List of sweetening agents in pharmacopoeias and/or GRAS listed and/or in the FDA list of inact
Sweetener Origin Sweetness
(compared to sucro
Acesulfame potassiuma Artiﬁcial sulﬁlimide ×130–200
Alitame Artiﬁcial dipeptide ×2000
Ammonium glycyrrhizate Natural glycoside ×30–50
Aspartame Artiﬁcial dipeptide ×180–200
Aspartame–acesulfame potassium Artiﬁcialmixed ×350
Cyclamate and calcium salt Artiﬁcial sulﬁlimide ×30
Cyclamate sodium Artiﬁcial sulﬁlimide ×30–50
Dextrose (glucose) Naturalmonosaccharide ×0.74
Erythritol Natural polyol ×0.7
Fructose Naturalmonosaccharide ×1.73
Glycerin (glycerol) Natural polyol ×0.6
Inulin Natural polysaccharide ×0.1
Isomalt Natural polyol ×0.4
Lactitol Natural polyol ×0.4
Maltitol Natural polyol ×0.9
Maltose Natural disaccharide ×0.3
Mannitol Natural polyol ×0.5
Neohesperidin dihydrochalcone Artiﬁcial glycoside ×1500–1800
Neotame Artiﬁcial derivated dipeptide ×7000–13,000
Saccharin Artiﬁcial sulﬁlimide ×300–500
Saccharin sodium, calcium Artiﬁcial sulﬁlimide ×300–500
Sorbitol Natural polyol ×0.6
Steviol glycosides Natural glycoside derivated ×40–300
Sucralose Artiﬁcial disaccharide ×400–800
Sucrose (saccharose) Natural disaccharide ×1
Tagatose Naturalmonosaccharide ×0.9
Thaumatin Natural protein ×2000
Trehalose Artiﬁcial disaccharide ×0.45
Xylitol Natural polyol ×0.95
PhEur — European Pharmacopoeia, USP-NF — United States Pharmacopoeia National Formular
a Also known as acesulfame K.
b Rebaudioside A.whereby the ﬂavouring is adsorbed onto excipients such as malto-
dextrins. Safety concerns such as possible risk of toxicity, allergies and
sensitization should be considered.
Two pieces of legislation adopted by the European Commission in
October 2012 [40] have been introduced to harmonise and clarify the
rules for using ﬂavouring substances.
- Regulation (EU 872/2012) providing for a new EU wide list of
ﬂavouring substances which can be used in food will apply from
22 April 2013. All ﬂavouring substances not in the list will be
prohibited after a phasing out period of 18 months.
- Regulation (EU 873/2012) concerning transitional measures for
other ﬂavourings such as those made from non-food sources will
apply from 22 October 2012.
The new list includes over 2100 authorised ﬂavouring substances,
which have been used for a long time and have already been assessed
as safe by other scientiﬁc bodies. A further 400 will remain on the
market until European Food Safety Authority (EFSA) concludes its
evaluation.ive ingredient for approved drug products and/or with an E number.
se)
GRAS status In FDA list of
inactive ingredients
E number Pharmacopoeia
– + E 950 PhEur; USP-NF; BP
– – E 956 –
+ + – PhEur; BP
– + E 951 PhEur; USP-NF; BP
+ – E 962 –
– + E 952 –
– + E 952 PhEur; BP
+ + – PhEur; USP; BP; JP
+ – E 968 PhEur; USP-NF; BP
+ + – PhEur; USP; BP; JP
+ + E 422 PhEur; USP; BP; JP
+ – – USP
+ + E 953 PhEur; USP-NF; BP
+ + E 966 PhEur; USP-NF; BP
+ + E 965 PhEur; USP-NF; BP
+ + – USP-NF; JP
+ + E 421 PhEur; USP; BP; JP
– – E 959 PhEur; BP
+ + E 961 USP-NF;
– + E 954 PhEur; USP-NF; BP; JP
– + E 954 PhEur; USP; BP; JP
+ + E 420 PhEur; USP-NF; BP; JP
+b – E 960 –
– + E 955 USP-NF; BP
+ + – PhEur; USP-NF; BP; JP
+ + – USP-NF;
+ – E 957 –
+ – – PhEur; USP-NF; BP; JP
– + E 967 PhEur; USP-NF; BP; JP
y, BP— British Pharmacopoeia, JP— Japanese Pharmacopoeia.
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Fig. 3. Sweetness intensity of various sweeteners as a function of time (reproduced with
permission from DeFer, 2010 [37]).
Table 4
Potential ﬂavours as a function of product character and product type (indication)
(adapted from CHMP, EMEA, 2006. Reﬂection paper: Formulation of choice for the paedi-
atric population [41]).
Product character Suitable ﬂavours
Acid Lemon, lime, grapefruit, orange, cherry, strawberry
Alkaline Aniseed, caramel, passion fruit, peach, banana
Bitter Liquorice, aniseed, coffee, chocolate, peppermint, grapefruit,
cherry, peach, raspberry
Metallic Berry fruits, grape, peppermint
Salty Butterscotch, caramel, hazelnut, spice, maple
Sweet Vanilla, grape, cream, caramel, banana
Product type Flavours often used
Antiulceratives Lemon, fresh and balsamic blends
Laxatives Cherry, raspberry, liquorice, aniseed, orange/vanilla blends
Mucolytics Orange/lemon blends, raspberry
Penicillins Cherry, raspberry, woodberry, tutti fruti, blends
Sulphonamides Vanilla, caramel, woodberry, apricot, cherry, blackberry, banana
Tranquillisers Aniseed/mint blends
Vasodilators Ginger, coffee, caramel
Vitamins Orange, lemon, tangerine, grapefruit, pineapple, tropical fruits
20 J. Walsh et al. / Advanced Drug Delivery Reviews 73 (2014) 14–33In general, a combination ofﬂavours is used to complement the taste
proﬁle of an API, and the selection of ﬂavours should be based upon the
taste characteristics of the drug to be taste-masked. Table 4 provides a
list of product character (ﬂavour type) together with ﬂavours that
have been found to be most successful at taste masking, together with
a list of ﬂavours often used for different product types (indications) in
Europe [41].
However the relevance of this information with respect to selection
of ﬂavours for paediatric formulations is debatable. It is a useful starting
point, although it implies that the taste characteristics of the API are
known which is rarely the case for drugs in early phase development.
In addition, the information appears to be somewhat derived from
adult marketing feedback and not according to age, gender and socio-
cultural background which will inﬂuence recognition and preference
of these ﬂavours or by evidence-based proof of increased compliance
in paediatric patients. Indeed, market research suggests that there are
“favourite” ﬂavours which vary from country to country [41]. During
the development of Coartem® dispersible tablets for the treatment of
uncomplicated Plasmodium falciparum malaria, three fruit ﬂavours
(cherry, orange, strawberry) were tested in Tanzanian children; the ﬂa-
vour, smell and sweetness of each were rated using a visual analogue
scale with smiley faces. Other easily-recognized ﬂavours such as banana
andmangowere not strong enough tomask the bitter taste of the drug.
Cherry was the overall preferred ﬂavour although unlike banana and
mango, this fruit is not native to Africa [42]. In many cases, it is prefera-
ble to develop a “taste neutral” medicinal product to avoid speciﬁc
ﬂavour recognition and preferences.
In order to simplify ﬂavour selection, the option of ﬂavouring the
medicinal product at the point of administration for each dose may be
considered. This would offer ﬂexibility (for example, day to day, region
by region, acute versus chronic dosing) and address preference issues.
However, compatibility of all the ﬂavours with the product would
need to be assessed including “in-use” shelf life.
Such an approach has been developed by FLAVORx [43] and is avail-
able in the USA, whereby commercial prescription liquid medicines can
be re-ﬂavoured (18 proprietary ﬂavours available) in participating
pharmacies. This is done either based on experience of successful
ﬂavourings or on patient choice. FLAVORx products are considered to
be food-grade itemsby the FDA. However, it should benoted that the in-
gredients in the FLAVORx add-mixture have not been tested for com-
patibility with each and every drug product and hence drug product
safety, efﬁcacy and stability could potentially be affected. In addition,
if the added volume of a premade liquid ﬂavouring product is substan-
tial, the concentration of API may become diluted. Another example of
ﬂavouring a medicinal product at point of dosing is Children's Tylenol
with Flavor Creator™, where the cherry based original over the counter
(OTC) paracetamol syrup can be customised at homewith stickpacks of
sugar free ﬂavouring granules (apple, bubblegum, chocolate, or straw-
berry) to sprinkle in each dosing cup at the time of administration.3.3. Safety and toxicity of sweeteners and ﬂavouring agents
As for other excipients discussed in this review, a risk based ap-
proach should be used for the selection of sweeteners and ﬂavouring
agents and there should be a strategy in place with 1st line, 2nd line
etc. choice.
For example, the use of cariogenic sweeteners can be balanced by
length of treatment and severity of disease or simply oral hygiene (rins-
ing the mouth with water after dosing). The use of carbohydrates with
potential to raise plasma glucose such as fructose, glucose or sucrose
should be strictly limited or possibly totally avoided in diabetic children
and adolescents [44]. When medicines are taken in small quantities for
limited periods, the sugar content is unlikely to cause problems, as it is
low in relation to the carbohydrate content of the whole diet. Sugar free
alternatives should be recommended if the medicine is for long term
use.
Sugar alcohols or polyols (Table 5) including hydrogenated mono-
saccharides (erythritol, xylitol, sorbitol, mannitol) and disaccharides
(isomalt, lactitol, maltitol) are low-digestible carbohydrates; they have
potential beneﬁts such as reduced caloric content, reduced or no effect
on blood glucose levels (low glycemic response) and a non-cariogenic
effect.
Glycerol (glycerin), the simplest polyol with 3 carbon atoms iswide-
ly used as sweet vehicle or co-solvent (relative sweetness of 0.6) in var-
ious oral liquid pharmaceutical products. ADI levels for polyols have not
been speciﬁed by the Joint Expert Committee on Food Additives
(JEFCA), although in varying doses they can cause gastrointestinal
symptoms such as bloating and laxation. Despite great variety in study
designs, protocols, and types of results, Grabitske and Slavin [45] in a
review of published studies reporting gastrointestinal effects of low-
digestible carbohydrates estimated some ADI for sugar alcohols
(Table 5). Nevertheless the limits for medicinal products are even
more conservative: if the maximum oral daily intake exceeds 10 g for
sorbitol, xylitol, mannitol, maltitol, isomalt, lactitol or glycerol, it is
necessary to provide information on the labelling as per the European
Commission guideline on Excipients in the Label and Package Leaﬂet
of Medicinal Products for Human Use (CPMP/463/00) [46]. It is
proposed that the current excipient labelling guideline, which was
implemented before the European Paediatric Regulation, is updated as
a number of safety concerns regarding excipients have not been
addressed, including the paediatric population [47].
Fructose is formed via the metabolism of polysaccharides such as
sucrose, and polyols such as sorbitol. Patients with rare hereditary fruc-
tose intolerance are missing aldolase B, a key enzyme in the further
Table 5
Solubility, cooling effect, hygroscopicity, estimated acceptable daily intakes, and caloric value of polyols.
Polyol Number of carbons Solubility in water 25 °C Cooling effect Hygroscopicity ADI (g/day)a Caloric value (kcal/g)
Erythritol 4 37% Very strong Low 40 0.2
Xylitol 5 64% Very strong High 30 2.4
Mannitol 6 20% Strong Low 20 1.6
Sorbitol 6 70% Strong High 30 2.6
Maltitol 12 60% Weak Low 40 2.4
Isomalt 12 25% Weak Low 40 2.4
Lactitol 12 57% Weak Low 30 2.4
Sucrose 12 67% Weak Low ~ 4
ADI — acceptable daily intake.
a Estimated by Grabitske and Slavin, 2009 [45].
21J. Walsh et al. / Advanced Drug Delivery Reviews 73 (2014) 14–33metabolism of fructose, normally present in the liver, kidneys and small
intestine. Patients with this condition should avoid medicinal products
containing fructose, sucrose, lactitol, maltitol (4-O-α-glucopyranosyl-
D-sorbitol), or sorbitol, in order to avoid fructose accumulation in
these organs. This intolerance can cause major hypoglycaemic crises,
liver damage, kidney malfunction, coma and death.
Very often intense sweeteners are needed to intensify the sweet
taste of a formulation especially to taste mask very bitter compounds.
Safety issues associated with intense sweeteners are different to those
of bulk sweeteners as the quantities used are inﬁnitesimal. Thus they
do not provide a heavy caloriﬁc burden (e.g. sucralose is poorly
absorbed), they elicit little or no glycaemic response and they do not
promote dental caries. The ADIs of intense sweeteners are provided in
Table 6 and speciﬁc safety concerns are discussed below.
Since aspartame is a methyl ester of the aspartic acid/phenylalanine
dipeptide, it is a source of phenylalanine and so it can be harmful to
patients with phenylketonuria. Although neotame is a derivative of as-
partame, it is not metabolised to phenylalanine and has the advantage
to be heat stable but with the same pH dependant stability (around
pH 4). There is inconclusive evidence that aspartame causes hyperactiv-
ity in children.
“Sulfa allergy” is a term used to describe adverse drug reactions to
sulphonamides. Cyclamate and saccharin are both sulphonamides and
so should therefore be avoided in patients with sulphonamide allergy.
Despite critiques by Grotz and Munro [48] and Brusick et al. [49], a
study by Abou-Donia et al. [50] showed that 100–1000 mg/kg of
Splenda® (a proprietary sweetener based on sucralose) gavaged to
male Sprague–Dawley rats for 12 weeks led to (1) reduction in beneﬁ-
cial faecal microﬂora, (2) increased faecal pH, and (3) enhanced expres-
sion levels of P-gp, CYP3A4, and CYP2D1, which are known to limit the
bioavailability of orally administered drugs. Additional safety studies
are warranted to determine the full impact of sucralose on drug
bioavailability and to evaluate the biological effects of chronic sucralose
usage particularly for special populations (e.g. children, elderly, nursing
mothers, persons with diabetes, cancer patients). However the quanti-
ties of sucralose likely to be used in formulations (less than 0.25%–
250 mg/100 ml in general) mean that the level of consumption
mentioned above is very unlikely to be met.
A review of the safety of ﬂavouring agents is out of scope of this
document and readers are recommended to interrogate the EU
Flavouring regulations previously described. When assessing a
ﬂavouring agent for its suitability for a paediatric patient, it is important
to consider the solvents or carriers used within the material.
In summary, the use of sweeteners is the simplest and often the ﬁrst
approach for taste masking. It is applicable to a wide range of solid and
liquid dosage forms and does not require specialist equipment for
manufacture. Bioequivalence is generally not of concern, except where
gastrointestinal transit may be accelerated. However it is not a platform
approach and is not particularly successful for taste masking extremely
bitter highly water soluble compounds. Flavours can have a complex
composition and may not be universally acceptable from a regulatory
and/or patient perspective. Flavours and sweeteners can be used inconjunction with other taste masking techniques discussed later in
this review.
4. Modiﬁcation of API solubility
The taste of an API can only be evoked if the compound is in solution
and able to interact with the taste receptors within the oral cavity. Oral
dosage forms where the drug remains undissolved in the oral cavity,
such as a suspension, can provide taste masking of aversive tasting
compounds, since the drug remains predominantly undissolved in the
formulation vehicle or saliva andbinding to the taste receptors is greatly
reduced. Maintaining solid status or driving the API out of solution
by utilising the physico-chemical properties of the free form or various
other sold forms (salt, cocrystal, polymorph), as well as use of prodrugs/
softdrugs that have poor solubility in the formulation vehicle or saliva
can, therefore, also provide taste masking of unpleasant tasting com-
pounds. A number of patents describing these approaches are available
and discussed below, whilst the use of prodrugs and softdrugs are not
discussed, since these techniques go beyond the scope of this document.
4.1. Keeping the API unionised
For compounds that are ionisable, with pH-dependent solubility
characteristics, utilising the pKa of the free form and ﬁxing the pH of
the formulation, so that the majority of the compound remains
unionised, can 1) greatly limit the solubility of the compound in the for-
mulation vehicle, 2) reduce rate of dissolution in saliva or 3) promote
in-situ precipitation during reconstitution. This approach has been
demonstrated by Wyley [51], who incorporated pH modiﬁers, such as
L-arginine, into a reconstituted suspension formulation of quinolone
carboxylic acid to maintain an alkaline pH once reconstituted in water,
reduce the solubility of the drug in the formulation vehicle and conse-
quently mask the bitter taste of the compound. A similar approach
was used in an ondansetron ODT formulation where sodium bicarbon-
ate was added to create an alkaline environment and reduce solubility
and the consequent taste perception of the drug [52]. The alkalising
agent anhydrous trisodiumphosphatewas also added to a reconstituted
suspension formulation for the antibiotic azithromycin to create a sus-
pension formulation where azithromycin had limited solubility and
thus reduced taste intensity [53]. To enable this technique to be used
inmedicinal products destined for children the pHmodifying excipients
and the concentrations used need to be appropriate and suitable for the
intended paediatric population.
4.2. Alternative solid form
During formulation development the solid form of the API can vary
and may only become ﬁxed during market formulation development
and when the drug substance synthesis is ﬁnalised. Selection of an
alternative solid form, such as a salt, cocrystal or polymorph, with low
solubility in the formulation vehicle or slower dissolution rate may,
therefore, be a viable option to enable taste masking of an unpleasant
22 J. Walsh et al. / Advanced Drug Delivery Reviews 73 (2014) 14–33tasting API. Alternative solid forms of an API have also been reported as
having differing tastes from one another and could therefore aid
palatability of a formulation. This approach has been demonstrated
with diclofenac [54], ibuprofen [55], and buspirone [56]. As per the
buffer systems mentioned previously, to enable this technique to be
used in medicinal products destined for children the counter ions and
coformers employed need to have acceptable safety in the paediatric
population in which the formulation is intended for.4.3. Challenges to consider for modifying an API
Applying modiﬁcations to the API, whilst being effective, does come
with various challenges and points to consider. First and foremost
pharmacokinetic (PK) performance and bioavailability utilising this
technique need to be assessed when any modiﬁcation to the API is
employed, since integral physicochemical properties of the API may be
altered that may alter the performance of the formulation. Keeping
the API unionised or using a poorly soluble salt form cannot be
employed successfully for unpleasant tasting compounds that have a
low taste threshold — i.e. compounds that evoke their taste perception
at low concentrations. This is because having a very small concentrationTable 6
Structures and acceptable daily intakes of intensive sweeteners.
Intensive sweetener ADI
mg/kg
Acesulphame K 15 (FDA, EFSA)
Aspartame 40 (EFSA)
50 (FDA)
Cyclamate 5 (EFSA)
Neohesperidin dihydrochalcone (NHDC) 5 (EFSA)
Saccharin 5 (FDA, JEFCA)
Steviol glycosides (expressed as steviol equivalents) 4 (EFSA)of drug dissolved in the formulation vehicle or saliva may be unavoid-
able and if the drug has a very low taste threshold it will still be tasted
despite most of the drug remaining undissolved. Applying modiﬁca-
tions to the API may also affect aftertaste — dissolution rates may alter
in various buffered systems or with differing solid forms and, therefore,
oral residence time might change. Modiﬁcations to the API may also
affect particle morphology that might inﬂuence mouthfeel of these
compounds in the oral cavity and should therefore be assessed where
possible. Utilising a ﬁxed pH to enable low solubility of an API in a sus-
pension formulation may also jeopardise any preservative system that
is being employed, since the majority of these systems are pH depen-
dent. The use of various buffer systems also needs to be monitored for
adverse effects. The low pH of oral liquid formulations has been associ-
ated with for example dental caries and tooth erosion [57].
In summary, modiﬁcation of API solubility is a beneﬁcial taste
masking technique for applicable compounds that have a low/moderate
level of bitterness, since commonly used excipients can be employed.
Care should be maintained, however, that these common excipients
have acceptable safety in the paediatric population. Despite numerous
patents showcasing this technique, there is a lack of clarity on the
approach used in marketed formulations and as such the beneﬁt of
this taste masking method in the paediatric population is not clear.Structure
Table 6 (continued)
Intensive sweetener ADI
mg/kg
Structure
Sucralose 15 (SCF)
5 (FDA)
Thaumatin 5 (EFSA) (Protein)
Neotame 2 (EFSA)
18 (FDA)
ADI — acceptable daily intake, FDA— United States Food and Drugs Administration, EFSA — European Food Safety Authority, JECFA — Joint Expert Committee on Food Additives, SCF —
Scientiﬁc Committee on Food.
23J. Walsh et al. / Advanced Drug Delivery Reviews 73 (2014) 14–335. Create a ‘molecular’ barrier around the API by complexation
5.1. Ion-exchange resins
Ion exchange resins (IER) are a molecular tool to bind unpleasant
tasting drugs and prevent interactions between the API molecule and
the taste receptors. The solid IER particles may be suspended in a pleas-
ant tasting vehicle and administered to the child as a liquid or the taste
masked particles can be compressed into conventional tablets or ODTs.
As ODTs directly disintegrate within the oral cavity they offer various
advantages for example are easy to swallow without the need for
water. Furthermore, IERmay act as superdisintegrants for tablet formu-
lations [58].
IER are high molecular weight polymers which are mostly insoluble
in water and contain acidic or basic functional groups with capability to
reversely exchange counter-ions within aqueous solution [59,60]. They
can be divided into two groups; strong and weak ion exchange resins
depending on the number and the chemical nature of ionic groups
contained within the resin. Most drug–resin complexes (so called “res-
onates”) are prepared by the batch method whereby a certain amount
of IER is dispersed in water and an excess of drug substance is addedwhile stirring (drug loading process). The batch is subsequently stirred
for a speciﬁed time until reaching the equilibrium of drug adsorption
and desorption which is pH dependent [61].
Some general considerations need to be made for choosing the ap-
propriate resin. The ionic characteristic of the API should be opposite
to the IER in order to obtain an anion–cation interaction. To ensure
taste masking, the resinate needs to be stable in the drug formulation
e.g. a suspension or a tablet formulation. In addition, the resinate must
not dissociate in the mouth, hence the complex should be stable at
pH 6–7 of the saliva [62,63]. However, at enteric pH conditions (pH
b 5), the drug should be rapidly and almost entirely released in order
to prevent reduced bioavailability.
5.1.1. Safety and toxicity of pharmaceutical grade ion exchange resins
The advantage of most resins is their high molecular weight and
therefore very low absorption from the gastrointestinal tract. Oral toxic-
ity is reported to be low for marketed IER (Table 7) and they are gener-
ally regarded as safe. However, studies with radio-labelled cationic
exchangers showed remarkable particle uptake in pigs and distribution
in several organs such as liver, kidney, spleen and skeletal muscle [64].
Moreover, it has to be considered whether the released counter-ion
24 J. Walsh et al. / Advanced Drug Delivery Reviews 73 (2014) 14–33may affect toxicology and safety data. Conversely, IER can be beneﬁcial
for reducing the acute toxicity of APIs or even detoxiﬁcation from
contaminants through binding. Becker and Swift [65] were able
to show this for 13 different APIs (e.g. DL-amphetamine phosphate,
dihydrocodeine bitartrate, ephedrine sulphate, pyrilamine maleate)
bound to two strong acid cation exchange resins (Amberlite™). The
anion exchange resin cholestyramine is widely used as an API at high
doses for binding bile acids in the intestine in order to reduce cholester-
ol blood levels.
5.1.2. Formulations suitable for the paediatric population
Characterization of drug–resin complexes and the success of taste
masking effect have been extensively described in the literature [9,11,
59,66–73]. Examples of successfully taste masked drugs by IER
complexes and related drug dosage forms that are relevant for paediat-
ric patients are provided in Table 8 and are discussed below.
Interestingly, most resinates were formulated into an ODT or chew-
able tablet rather than into a liquid suspension. When developing a
formulation with suspended resinate, it is important that the resinate
does not interact with the excipients of the suspension base and the
pH should be adjusted to prevent dissociation of the drug from
the resin. Furthermore, the IER may act as a solid phase catalyst for
API degradation. This has been recently shown for methylthionium
chloride, also known as methylene blue [61], which underwent
demethylation in the presence of the employed IER [74]. In contrast, a
stable oral suspension of quinine sulphate complexed by Indion 234
has been developed [75].
For extremely bitter tasting tramadol hydrochloride, mechanically
robust mouth-dissolving tablets (MDT) with rapid disintegration
could be obtained. Shaking the drug resin (Tuslion 335) complex in
phosphate buffer (pH 6.8) did not show any drug release after 300 s.
Therefore, taste masking was assumed to be successful [76]. Puttewar
et al. [77] prepared ODTs with a doxylamine-Indion 234 complex
using crospovidone. Stability of the resinate in a simulated saliva ﬂuid
could be shown and taste masking was conﬁrmed by a human taste
panel (n = 10). Risperidone taste masked ODTs were prepared and
assessed in vitro by release studies in artiﬁcial saliva as well as in vivo
by six human volunteers [78]. Mouth-dissolving pellets containingTable 7
Toxicity data on pharmaceutical grade ion exchange resins.
Excipient name Functional group Counter ion Brand na
Strong acid cation-exchange resin
Styrene/divinyl benzene co-polymer –SO3− –H+ Indion®
Sodium polystyrene sulfonate USP –SO3− –Na+ Amberlit
Indion®
Tulsion®
Weak acid cation-exchange resin
Polacrilin potassium USP/NF –COO− –K+ Amberlit
Indion®
Tulsion®
Cross linked polyacrylic matrix –COO− –K+ Indion®
Indion®
Polacrilex resin –COO− –H+ Amberlit
Tulsion®
Cross linked polyacrylic matrix –COO− –H+ Indion®
Indion®
Strong base anion-exchange resin
Cholestyramine resin USP/EP –N+R3 –Cl− Duolite™
Duolite™
Tulsion®
Indion®
Weak base anion-exchange resin
Styrene/divinyl benzene co-polymer –N+R2 –H+ Amberlit
Toxicity data provided by ion-exchange resin suppliers: Ion Exchange India Ltd, http://www.ion
ticals/Tastemasking.htm; Thermax, India, http://www.thermaxindia.com/Chemicals/Ion-Exchataste masked fexofenadine hydrochloride bound to Indion 234s and
254 were developed and produced by extrusion–spheronisation [79].
Taste masking and smooth mouthfeel were conﬁrmed for the Indion
234s resinate by a human adult taste panel (n= 10), but not for Indion
254 which showed poor mouthfeel despite taste making capabilities.
Metoclopramide resinate was directly compressed or granulated by
melt granulation with mannitol or xylitol and then compressed to
ODTs [80]. Assessment of taste masking was not described. Ambroxol
hydrochloride containingODTs could be obtained by direct compression
with mannitol. No bitter taste was rated by a panel of 6 healthy volun-
teers and a smooth mouthfeel was described [81]. Diphenhydramine
hydrochloride was formulated into effervescent and dispersible tablets
with improved palatability after binding to Indion 234 and Tulsion 343
as rated by 20 male volunteers [82].
These studies showed that unpleasant tasting APIs can be efﬁciently
taste masked with different strong and weak IER and how these resins
can be further processed into dosage forms in order to obtain a child-
appropriate drug formulation. Challenges for ODTs are goodmechanical
strength with a rapid disintegration and a pleasant mouthfeel at the
same time. Stability of the resin also has to be taken into account for
both solid and liquid dosage forms.
5.2. Cyclodextrins
Cyclodextrins (CD) are cyclic oligosaccharideswhich have a cup-like
structure and are able to form inclusion complexes with other mole-
cules, in both aqueous solutions and the solid state. The nomenclature
of CDs is derived from the number of glucose units, for example, α CD
contains 6 units, β CD contains 7 units and γ CD contains 8 units of glu-
cose. β CD is the most commonly used CD and is primarily used in oral
formulations, whilst α CD is used mainly in parenteral formulations
[84]. CDs are water soluble due to the large number of hydroxyl groups
present, although solubility can be increased via chemical modiﬁcation
by for example the introduction of other functional groups. The inner
cavity of CDs tends to be relatively polar and is therefore hydrophobic,
whilst the exterior is hydrophilic. This means that CDs are capable of
interacting with a variety of molecules whereby whole or part of the
guest molecule ﬁts into the CD cavity. This results in the physical andme Oral toxicity — LD
50 in mice (mg/kg)
Comment
244 5500 Not absorbed by body tissues (non-toxic)
e™ IRP69 10,000 (Indion 254) Not absorbed by body tissues (non-toxic)
254
344
e™ IRP88 3000 (Indion 294) Not absorbed by body tissues (non-toxic)
294
339
414 10,000 (Indion 414) Not absorbed by body tissues (non-toxic)
234
e™ IRP64 Not absorbed by body tissues (non-toxic)
335
204 4500 Not absorbed by body tissues (non-toxic)
214 10,000
AP143/1083
AP143/1093
412 (CHL)
454
Not absorbed by body tissues; used as API
for detoxiﬁcation or to treat
hypercholesterin-aemia
e® IR 4B Not absorbed by body tissues (non-toxic)
resins.com/pharma.htm; Rohm andHaas, http://rohmhaas.com/ionexchange/pharmaceu-
nge-Resins/Speciality-Resins/Pharmaceutical-Resins.aspx.
Table 8
Ion exchange resins used for taste masked drug formulations.
Excipient Drug Dosage form In vitro testing In vivo testing Reference
Indion 204, 234, Tulsion 335, 339 Quinine sulphate Suspension ✓ ✓ [75]
Indion 204 Etorocoxib Suspension ✓ ✓ [70]
Amberlite IRP 69F Dowex 50*8-100 Codeine phosphate Suspension ✓ – [83]
Indion 234, 234s, 254, 294 Amberlite IRP-64, IRP 69,IRP 88 Methylene Blue HCl Suspension ✓ ✓ [74]
Indion 234s, 254 Fexofenadine HCl Melt-in-mouth pellets – ✓ [79]
Tulsion 335 Tramadol HCl Mouth-dissolving tablets ✓ – [76]
Indion 234, Tulsion 343 Diphenhydramine HCl ODTs
Effervescent tablets
✓ ✓ [82]
Indion 204, 234 Ambroxol HCl ODTs ✓ ✓ [81]
Amberlite IRP64 Risperidone ODTs ✓ ✓ [78]
Indion 244 Metoclopramide HCl ODTs nd nd [80]
Indion 204, 234, 414 Doxylamine succinate ODTs ✓ ✓ [77]
Kyron T 134 Atomoxetine HCl ODTs ✓ – [72]
Amberlite IRP-69 Dextromethorphan HBr ODT ✓ ✓ [73]
nd— not done, ODT — oro-dispersible tablet.
25J. Walsh et al. / Advanced Drug Delivery Reviews 73 (2014) 14–33chemical properties of the entrapped molecule being modiﬁed. It is for
this reason that CDs have a variety of applications, via various routes
of administration, including increasing bioavailability, solubility and
stability as well as decreasing the taste perception of a drug. The size
of the molecule to be complexed is a major factor that determines
which CD is best suited for complexation. For example, α CD has a
smaller cavity and thus preferentially forms inclusion complexes with
slender guestmolecules such as aliphatic chainswhilstβ CD is appropri-
ate for aromatic rings [10,85–87].
It is believed that the extent of taste masking depends upon the
amount of free drug available. Two theories have been reported;
(i) the CD enwrap the bad tasting molecule impeding its interaction
with the taste buds, and (ii) the CD interacts with the gate-keeper
proteins of the taste buds, paralysing them [86]. However, it is believed
that the latter theory is less likely since this would result in all taste sen-
sations being blocked, which is not true. Furthermore, it has been
reported that the bitter taste of an API only disappears in the presence
of CD when it has formed a complex with it.
5.2.1. Oral safety and toxicity of cyclodextrins
Animal toxicity studies inmice, rats and dogs have shown that orally
administered CDs are essentially non-toxic, which is believed to be
due to a lack of absorption through the gastrointestinal tract. Indeed,
β CD LD50 for mice, rats and dogs have been reported as N12.5 g/kg,
18.8 g/kg and 5 g/kg respectively [88,89]. Administration of β CD at
concentrations of up to 1.25% in the diet of rats did not cause any devel-
opmental toxicity. However, when given at a dietary concentration of
5%, treatment of lactating rats caused retarded pup growth. The cause
of this is not known although it is postulated that it may have been
due to a change in milk yield as the females consumed slightly less
food during the lactation period. β CD was not excreted in the milk
and indeed there were no differences in milk composition. There were
no permanent defects to the pups and no adverse events were seen as
a result of treatment with β CD during gestation [88].
The toxicity of hydroxypropyl (HP)β CDhas been investigated and it
is considered that this molecule has nomutagenic potential, no adverse
effects on fertility nor peri and post natal development. However, an in-
crease in theweight of the pancreaswas reported following a 25 month
carcinogenicity study in which HPβ CDwas dosed orally to rats at up to
5 g/kg per day. The authors believe, however that the hyperplastic effect
observed is a rat-speciﬁc phenomenon, although additional studies are
recommended [89]. Thackaberry et al. [90] have done further studies
on HPβ CD in mice, rats, dogs and cynomolgus monkeys. It was found
that the oral administration of HPβ CD to dogs and monkeys at a dose
of 1000 mg/kg resulted in an increase in loose/soft stools, whilst this
only increased minimally in male dogs at a dose of 500 mg/kg. When
rats and mice were administered the same doses, a time and dose
dependent increase in serumAST andALT levels was observed in femalerats whilst four out of ﬁve male mice had minimally elevated ALT levels
in the 1000 mg/kg group. These observationswould suggest progression
of hepatic toxicity although macroscopic and microscopic examinations
of the livers were normal and similar to controls. The nature and toxico-
logical signiﬁcance of elevated transaminase levels in rodents is not
known. However, this could have an impact on the interpretation of
drug toxicity studies should HPβ CD be used in pre-clinical formulations.
CDs are poorly absorbed in the human gastrointestinal tract and it is
generally recognised that this is due to their bulky and hydrophilic
nature [89]. β CD is poorly digested in the human small intestine and
is almost completely degraded by the microﬂora in the colon. A daily
consumption of 10 g in human adults increases the faecal excretion of
biﬁdobacteria [91]. HPβ CD is well tolerated in humans and considered
to be non-toxic when administered orally [90]. Indeed, doses of 4–8 g
daily for one to two weeks were well tolerated. However, an increase
in the incidence of soft stools and diarrhoea has been observed when
doses of 16–24 g were given for 14 days. Based on these ﬁndings, HPβ
CD is considered to be acceptable at daily doses below 16 g [89]. From
a review of the literature, it has not been possible to determine themax-
imum tolerated dose of CDs for babies and children. Based on the above
observations, it is considered likely that if CDs are given in large doses to
paediatric patients they may experience diarrhoea.
5.2.2. Formulations containing cyclodextrins for taste masking
The effectiveness of CDs tomask the taste of anAPIwill depend upon
the dose and properties of the API, the CD selected and also the formu-
lation type and composition. This technology needs to be optimised on a
case-by base basis. Consideration needs to be given to the potential
impact the formation of inclusion complexes may have on the PK and
bioavailability of the drug and also any potential interactions with
other excipients, for example preservatives, which may compete for
complexation with the CD and alter the CD–drug inclusion complex
equilibrium. Furthermore, the use of CDs may not be practical for high
doses of API, especially if a high ratio of CD to API is required to achieve
taste masking.
Despite these challenges, numerous examples of investigations into
the development of taste-masked drug formulations using CDs exist
in the literature, including patent applications. Products containing
drug–CD complexes have also been marketed across the Globe, al-
though the vast majority utilise CD ability to increase solubility instead
of their taste masking properties [11,85,86].
Examples of bitter compounds that have been taste-masked using
CDs are presented in Table 9, some of which are in formulations that
may be suitable for paediatric patients. The utilisation of ternary com-
plexes of CDs with various polymers has also been evaluated and in
some cases has been found to have superior taste masking properties
compared to CD–drug complexes. However it should be noted that the
safety and tolerability of such complexes do not appear to have been
26 J. Walsh et al. / Advanced Drug Delivery Reviews 73 (2014) 14–33fully evaluated. Further examples of the application of CDs for taste
masking are provided by Arima et al. [87].
Although there has clearly been research into the formulation of CD
containing products that may be potentially administered to children,
there do not appear to be many examples of the use of CDs for taste
masking in licensed paediatric oral formulations. Nicorette® microtabs
(McNeill Products Ltd) and Boots NicAssist® microtabs (The Boots
Company) sub-lingual tablets utilise CDs for taste masking nicotine.
These products are approved in some territories for adults and children
over 12 years for the relief of nicotine withdrawal symptoms as an aid
to smoking cessation. Children's Zyrtec® Chewable tablets (McNeill-
PPC) contain taste masked cetirizine and are licensed for the relief of
symptoms of hay fever and other upper respiratory allergies in children
from the age of 6 years.
Due to the technical challenges associated with the use of CDs to
achieve optimal taste masking, this is not considered to be a platform
technology for taste masking in paediatric medicines.6. Apply a physical ‘barrier’ on the API or the dosage form
Anumber of platform technologiesmaybeutilised in order to create a
physical “barrier” on the API or dosage form, some ofwhich are discussed
below.Table 9
Examples of in vivo taste masking with cyclodextrins (human volunteers).
Drug/bitter compound Cyclodextrin Drug:cyclodextrin ratio
Diclofenac sodium ß CD 1:1
Artichoke extract, caffeine,
gentian extract, aloe extract
α CD
ß CD
γ CD (alone and linked
to chitosan)
0.4 and 1.2% of CD and
various drug concentrations
Naringin, limonin, caffeine Macromolecular
derivatives of ß CD and
γ CD bound to
carboxymethyl-chitosan
and
carboxymethyl
cellulose-chitosan
0.4 and 1.2% of CD
derivatives and various drug
concentrations
Primaquine phosphate ß CD 1:1, 1:5, 1:10, 1:15, 1:20,
1:25
Famotidine ß CD (also with HPMC
as a ternary complex)
1:1
Artemether ß CD 1:1, 1:5, 1:10, 1:15, 1:18,
1:19, 1:20
Levocetirizine dihydrochloride HP ß CD 1:3
Famotidine ß CD
SBE ß CDa HP ß CD
(with and without
povidone K30)
1:1
Rizatriptan benzoate ß CD 1:1, 1:2, 1:4, 1:6, 1:8, 1:10,
1:12, 1:14, 1:16
Oseltamivir phosphate ß CD 1:1
Diphenhydramine hydrochloride
Hydroxyzine dihydrochloride
Cetirizine dihydrochloride
Chlorpheniramine maleate
Epinastine hydrochloride
α CD
ß CD
γ CD
HP–ß CD
1.0 or 5.0 mMdrug in 10, 20
and 30 mM solutions of CDs
CD— cyclodextrin, HPMC— hydroxypropyl methylcellulose, SBE — sulfobutyl ether.
a Brand name Captisol®.6.1. Polymer ﬁlm-coating
Multiparticulates, for example mini-tablets, granules or pellets, are
multiple-unit dosage forms which are often presented in sachets or
stick packs, and are preferred to conventional tablets in almost every
age group according to the EMA reﬂection paper “formulations of choice
for the paediatric population” [41]. Thesemultiparticulate dosage forms
offer the possibility of individual dosingwith a low risk of dose dumping
and there are also easy to swallow. In addition, they can be further
dispersed in a pleasant tasting suspension base or administered with
food.
Tastemasking of these dosage forms can be achieved by introducing
a saliva-resistant barrier onto the outside of a particle, pellet, or tablet.
Therefore, the unpleasant API cannot directly interact with the taste
buds on the tongue. Polymer coating of solid particles, pellets or
(mini) tablets can be carried out using conventional coating processes,
for example in ﬂuidized bed systems or in a drum coater. Further
coating can be achieved by granulation–spheronisation, by spray
drying, or microencapsulation [10]. Coating may be achieved by using
aqueous dispersions, organic solvents or solvent-free processes, de-
pending on the properties of the coating material [9,34].
A major prerequisite to use a polymeric coating material as a taste
masking excipient is its ability to act as an insoluble barrier at pH of
saliva (pH 6–7) [62,63]. In general a number of polymeric excipientsPreparation and formulation Taste-masking properties Reference
Freeze-dried aqueous solution
(other taste masking techniques
also evaluated)
Mostly acceptable but short lived [92]
Chitosan, CDs and chitosan — CDs
dissolved in solutions of the test
compounds
1.2% chitosan— ß CDmost effective [93]
CD soluble derivatives dissolved in
solutions of the test compounds
1.2% γ CD carboxymethyl-cellulose
and 1.2% ß CD carboxymethyl
chitosan most effective
[94]
Physical mixing or kneading.
Complex incorporated into dry
suspension for constitution
formulation
1:25 ratio by physical mixing best [95]
Freeze-dried aqueous solution.
Physical mixture of drug, ß CD and
HPMC also prepared
Ternary complex best, drug–ß CD
complex better than physical
mixture.
[96]
Physical mixing or kneading.
Complex incorporated into dry
suspension for constitution
formulation
1:20 ratio by physical mixing best [97]
Fast dissolving ﬁlms of water
soluble polymers prepared by
solvent casting
Good [98]
Freeze-dried aqueous solution,
physical mixing, or kneading
(with and without povidone K30).
SBE ß CD-povidone N SBE ß
CD N HP ß CD povidone N
HP ß CD N ß CD povidone N ß CD
[99]
Physical mixing or kneading.
Aqueous dispersions prepared and
tasted.
Optimized taste-masking observed
with 1:10 kneading
[100]
Freeze-dried aqueous solution Bitter taste of drug improved [101]
Aqueous solutions HP–ß CD and ß CD more effective
than α CD and γ CD
[102]
27J. Walsh et al. / Advanced Drug Delivery Reviews 73 (2014) 14–33could be used for taste mask coating. However, it is important that the
intended API release proﬁle should not be compromised and so the coat-
ing barrier should dissolve after passing themouth at enteric pH (pH b 5).
Consequently, water soluble ﬁlms and pHdependent, acid-soluble ﬁlms
can be used. Stability andmasking efﬁciency of a water soluble ﬁlm can
be controlled by the thickness of the ﬁlm. The main advantage of pH
dependent, salivary resistant ﬁlms is that they only dissolve at enteric
pH and can therefore be dispersed in suspension bases or sprinkled on
food. Water soluble polymer coatings might release the API too early
resulting in the detection of the bitter taste. This may be mitigated by
using a mixture of water soluble and water insoluble polymers.
As stated previously, ODTs offer many advantages and may be espe-
cially suitable for paediatric and geriatric patients. However, a taste
masking coating applied to the API or granulates may rupture during
compression or if the tablet is chewed. To overcome this problem, mi-
croencapsulation has been developed for taste masking API particles.
It has been reported thatmicroparticles remained intact without under-
going merging or rupturing during tableting and hence taste masking
was ensured when the microparticles were incorporated ODTs [103].
The small-sized taste masked particles (microparticles) can be pre-
pared through spray drying, phase separation (coacervation) or through
solvent evaporation. For spray drying, the polymer is dissolved in a
suitable solvent and API added to form a solution or suspension and
then the solvent is evaporated through spray drying. The phase-
separation and solvent evaporation methods are based on an emulsion
of an aqueous drug solution and a polymeric organic solution. This
water in oil (w/o)-emulsion is then either dispersed in a large volume
of a polyvinyl alcohol containing aqueous phase, which leads to coacer-
vation, or a phase separator like silicon oil is added, which also leads to
polymer coacervation of the API particles. Usually organic solvents have
to be used and suitable techniques have to be applied to remove these
from the formulations which is a clear disadvantage. The residual
solvent levels need to be as low as possible, especially for children,
which might be challenging. In the literature, the preparation of taste
masked diclofenac sodium microcapsules has been described by Al-
Omran et al. [104], and Hashimoto et al. [105] have described the tasteTable 10
Toxicity data on pharmaceutical grade coating excipients.
Excipient name Brand name Oral t
Water soluble polymers
Macrogol poly(vinylalcohol) grafted copolymer
Ph. Eur.
Kollicoat® IR Rat: N
Ethylene glycol and vinyl alcohol graft copolymer
USP/NF (draft)
HEC (hydroxyethylcellulose Ph. Eur.) Various –
HPC (Hydroxypropylcellulose Ph. Eur.) Various Rat: 1
HPMC (hydroxypropylmethylcellulose,
hypromellose Ph. Eur.)
Various Rat: N
MC (methylcellulose Ph. Eur.) Various –
CMCNa (carboxymethylcellulose sodium,
carmellose sodium Ph.Eur.)
Various Rat: 1
Guine
pH dependent soluble polymers
Basic butylated methacrylate copolymer Ph. Eur.
Amino methacrylate copolymer USP/NF
aminoalkyl methacrylate copolymer E JPE
Eudragit® E (100; PO)
(soluble at pH b 5)
Mous
Rat: N
Methacrylic acid — Ethyl acrylate copolymer
(1:1) (L30 D-55 = Dispersion 30%) Ph.Eur.
Methacrylic acid copolymer
(L30 D-55 = Dispersion)— NF USP/NF
Methacrylic acid copolymer LD JPE
Eudragit® L (30 D-55; 100-55)
(soluble at pH N 5.5)
Mous
Rat: a
(LD50
Dog: a
(LD50
HPMCP (hydroxypropylmethylcellulose
phthalate, hypromellose phthalate Ph. Eur.)
– (various) (soluble at pH N 5.5,
but insoluble in saliva)
–
Toxicity data on branded polymers provided polymer coating suppliers: Evonik Industries, htt
default.aspx; BASF, http://www.pharma-ingredients.basf.com/Kollicoat/Home.aspx.masking of salts of basic drugs using a water in oil in water (w/o/w)
emulsion solvent evaporation method to produce microspheres. The
production of taste masked famotidine microspheres by a spray drying
[103] or the spray coating of diclofenac using Eudragit® EPO resulted in
taste masked formulations [106]. Fast-disintegrating tablets containing
microparticles with taste masking properties have been described in a
patent by Dobetti [107]. The microparticles were prepared by a phase
separation method and contained ibuprofen as a model drug.
Recently, the use of polymers in combination with lipids using hot-
melt extrusion has been introduced as an alternative taste masking
technique [108,109] where, for example, anionic active substances can
interact with the functional groups of positively charged polymers.
These interactions facilitate the creation of hydrogen bridge bonding
and consequently mask the active's bitter taste. Paracetamol and
ibuprofen have been successfully embedded within a Eudragit® EPO
polymer matrix and the latter incorporated in ODT formulations [110,
111].
6.1.1. Safety and toxicity of coating materials
Table 10 shows commercially available pharmaceutical grade coat-
ing materials which can be used for taste masking.
Toxicity issues can be associated with polymers having an ionic
structure. These polymers are of high molecular weight and therefore
have limited absorption in the body. Nevertheless, ionic functional
groups could randomly interact with body's tissues and therefore ad-
verse effects could occur. Facts regarding the safety proﬁles of these
polymers which are known today are summarised below.
According to the “WHO Food additives Series 26” [112] celluloses
(including ethylcellulose (EC), hydroxyethylcellulose (HEC), hydroxy-
propylcellulose (HPMC), (also known as hypromellose), methyl-
cellulose (MC), and carmellose sodium) have low oral toxicity.
Therefore the ADI was declared as “not speciﬁed” for food additives.
The only adverse effect which was observed was laxative effects. Fur-
thermore, HPMC (listed as hypromellose) and EC can be found on the
FDA list of food additives that are generally recognized as safe. (GRAS)
[36].oxicity — LD50 (mg/kg body weight) Comment
2000 Oral bioavailability in rats b 1% (with dosages of
10 and 1000 mg/kg)
Increased food consumption in rats, no toxicity
in man
0,200–15,000 –
1000 Light laxative or constipation effect in men
GRAS for general use in food at intake levels
up to 20 g/p/d (GRAS Notice No. GRN 000,213)
Single oral doses of 5 and 10 g were well
tolerated in man
5,000–27,000
a-pig: 16,000
No toxic effects in man were observed
e: N15,000
3000
Loss of weight due to food absorption effects
might occur
Inﬂuence on the water and electrolyte balance
e: N2000
bsence of toxic effects at 28,200 mg
therefore not determined)
bsence of toxic effects at 9100 mg
therefore not determined)
–
No toxic action has been found in rats and dogs
[115]
p://eudragit.evonik.com/product/eudragit/en/products-services/eudragit-products/Pages/
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tions are methacrylate copolymers. Various types and grades of
Eudragit® are approved and listed in US FDA's “Inactive Ingredients
for Approved Drug Products” list. However, as previously discussed,
there are still safety concerns regarding polymers with ionic structure.
The EFSA scientiﬁc opinion on the safety of neutral, basic and anionic
methacrylate copolymers for use as food additives (glazing agents) con-
cluded that the use of thesematerials in solid food supplements is not of
a safety concern at the proposed levels. The estimated daily exposures
were 46.7 mg/kg body weight/day for high adult consumers and
32 mg/kg body weight/day for children (4–17 years, 25 kg body
weight) for neutral copolymer, and 23.4 mg/kg body weight/day for a
60 kg adult and 16 mg/kg body weight/day for children (4–18 years)
for anionic and basic copolymer. The properties and toxicology of basic
and neutral methacrylate copolymers have recently been reviewed
[113,114], from which there appear to be different views between the
authors and EFSA regarding estimated daily exposures for the neutral
copolymers. The authors proposed an ADI level of 20 mg/kg body
weight for basic polymethacrylate and an ADI of 18–20 mg/kg body
weight for neutral polymethacrylate. Various new polymers are under
development, for example Kollicoat Smartseal®, which is a methacry-
late co-polymer. However, many of such new polymers have not been
used in commercially availablemedicinal products. Although themajor-
ity of suppliers of these excipients appear to have conducted extensive
toxicity studies in animals (mice, rats and dogs) as well as in vitro cell
based studies, there is a lack of published data regarding safety and
toxicity in humans, especially in the paediatric population.
It should be noted that coating formulations often contain additional
excipients, for example pore formers, glidants and plasticizers. There-
fore, safety and toxicity of the whole formulation needs to be consid-
ered. Due to differences in surface area and shape of particles, pellets
andmini-tablets, the amount of polymer for coating is higher for pellets
and granulates than for mini-tablets. Conversely, the amount of glidant
needed to prevent stickingduring the coatingprocessmight be different
for pellet, granulate and mini-tablet coating. This has to be taken into
account together with the intended dose to be administered when
selecting the dosage form in relation to the total amount of coating
excipients.Table 11
Examples of polymeric coating excipients used for formulations suitable for paediatrics.
Excipient Drug Dosa
Hypromellose/ethylcellulose Ibuprofen Core
Hypromellose phthalate Erythromycin
Clarithromycin
Carb
incor
Hypromellose/ethylcellulose Sparﬂoxacin Fine
Macrogol poly(vinylalcohol) grafted copolymer Ph. Eur.
Ethylene glycol and vinyl Alcohol Graft Copolymer
USP/NF (draft)(Kollidon IR)
Paracetamol Oral
Basic butylated methacrylate copolymer Ph. Eur.
(Eudragit® E PO)
Theophylline Table
Basic butylated methacrylate copolymer Ph. Eur.
(Eudragit® E PO)
Quinine sulphate Pelle
Methyl methacrylate and diethylaminoethyl
methacrylate co-polymer
Kollicoat Smartseal
Ornidazole Fine
Anionic methacrylate copolymer (Eudragit® L) Esomeprazole Oral
Basic butylated methacrylate copolymer Ph. Eur.
(Eudragit® E PO)
Terbinaﬁne Oral
Basic butylated methacrylate copolymer Ph. Eur.
(Eudragit® E PO)
Dexmethylphenidate Pelle
Ethylcellulose Tenovir Oral
Ethylcellulose Sodium valproate Oral
Hypromellose/ethylcellulose Ibuprofen Oral
Polymethacrylate (Eudragit® E100)/polyacrylate
dispersion 30 %
Paracetamol Oral6.1.2. Formulations suitable for the paediatric population
Coating of solid dosage forms in order to mask the unpleasant taste
of a drug has been described before by Douroumis [10], and a patent
review considering coating materials used for taste masking has been
conducted by Ayenew et al. [9]. Therefore, the coating of dosage forms
that are age appropriate is considered in this section, as well as data
on experiences with the administration of these dosage forms to paedi-
atrics. Table 11 shows examples of taste masked child appropriate
dosage forms.
Quinine sulphate, which is a very bitter tasting API, could be taste
masked via coating of pellets (size: 300–700 μm), which were obtained
by a wet-extrusion–spheronisation process [116,117]. 20% (w/w) of
Eudragit® E PO was required to mask the bitter taste sufﬁciently and
to obtain a homogeneous ﬁlm. The API could be released immediately
in acidmediumafter showing a different release rate inwater compared
to uncoated pellets. In a following bioavailability study in children
b 5 years and adults, it could be shown that the bioavailability of the
taste masked pellets was similar to that of commercially available
tablets. Furthermore, no pellets were rejected by the patients due to
unpleasant taste and all 56 children completed the 14-day follow-up.
Shirai et al. [118] prepared a ﬁne granule system containing
sparﬂoxacin, a bitter tasting antibacterial drug, and low-substituted
hydroxypropylcellulose (L-HPC). Taste masking could be carried out
by coating the granules containing 52% L-HPC with EC/HPMC (4/2)
and a 10% coating level. Due to this excipient combination, taste
masking was sufﬁcient, whilst rapid dissolution of the drug was still
possible and bioavailability, tested in dogs, was not affected compared
to rapidly releasing tablets. Bitter tasting ibuprofen particles were coat-
ed with amixture of EC and HPMC (2:3) in a ﬂuidized bed process [119,
120] andhealthy human volunteers evaluated particleswith aﬁlm coat-
ing N 10% aswell masked. Binding to an ion exchange resin was not suf-
ﬁcient enough for taste masking in the case of binding erythromycin
and clarithromycin to carbopol (polyacrylic acid) [121] and taste
masking by coating with hypromellose phthalate was achieved.
Eudragit® E PO pellets containing theophyllinewere prepared using
a powder coating process [122]. Taste masking was conﬁrmed by de-
layed dissolution at pH 6.8. At pH 1.0, simulating enteric pH, immediate
release of the drug could be observed. No solvents or liquid plasticizersge form Paediatric use Reference
particles – [119,120]
opol adsorbates
porated in a suspension
– [121]
granules – [118]
disintegrating tablet – [124]
ts (powder coating process) – [122]
ts Bioavailability
study in children
[116,117]
granules – [125]
granules for suspension ✓ Nexium®
granules/minitablets ✓ Lamisil®
ts ✓ Focalin®
granules ✓ Viread®
granules/minitablets ✓ Orﬁril®
disintegrating tablet ✓ Nurofen for Children Meltlets®
disintegrating tablet ✓ Calpol Six Plus Fastmelts®
29J. Walsh et al. / Advanced Drug Delivery Reviews 73 (2014) 14–33were used in the powder coating process, offering the advantage to re-
duce safety and toxicity concerns for a child appropriate formulation.
Pearnchob et al. [123] evaluated the ability of shellac as taste masking
material in comparison to HPMC. Lower coating levels of shellac were
needed compared to HPMC to obtain the same masking effect. In addi-
tion, drug release at gastric pH was not signiﬁcantly decreased by thin
shellac coatings.
In conclusion, taste masking via introduction of a barrier has already
been undertaken for child appropriate dosage forms. Eudragit® EPO
and Hypromellose (HPMC) in combination with other cellulose deri-
vates were the most commonly used materials as they offered the
advantage of not inﬂuencing the immediate release of a drug.
6.2. Lipidic barrier system
Although lipid excipientsmay be used to confer controlled/delayed
release properties on a medicinal product [126], they present an at-
tractive alternative to standard polymer coatings for taste masking
as they only require melting before application directly onto the sub-
strate. Furthermore, solvent evaporation is not required and thus
powders with very high speciﬁc surface areas can be coated rapidly.
Also, since the lipid is not diluted with solvents, higher and more uni-
form application rates are feasible compared to other techniques. As
the process is water-free this taste masking technology is suitable
for moisture sensitive APIs and the risk of microbial contamination is
reduced.
Triglycerides, mixtures of long chain mono-, di-, and triglycerides
and waxes used as coating agents provide several noteworthy advan-
tages: (i) the amount of excipient required to achieve the desired effect
is generally less compared to polymers; (ii) usually only one excipient is
required simplifying the formulation and hence the registration of the
drug product with regulatory authorities; (iii) they are plastic com-
pounds which do not crack during compression into tablets; (iv) they
are not soluble in ethanol and drug release should therefore not be
inﬂuenced by the presence of alcohol in the dissolutionmedium; and ﬁ-
nally (v) theymight be relatively inexpensive in comparison to polymer
coatings resulting in lower production costs.
A number of different lipid excipients and technologies can be used
for taste masking purposes, for example, hot-melt coating, spray
congealing, melt extrusion or melt granulation. However, choosing the
appropriate excipient for the application requires an understanding of
their physico-chemical properties and its associated effect on API
release and taste masking efﬁciency.
Hot-melt coatingwith lipid excipients offers an attractive alternative
to polymer ﬁlm coating since, as stated above, the lipid coating agent is
directly applied onto the drug substance without any solvent. Thus
there are no issues regarding residual solvent levels which can be of
particular concern to young children. Jannin et al. [109] and Repka
et al. [127] give a detailed overview of hot-melt technologies and appli-
cation for pharmaceutical use.
In order to produce small solid taste masked lipid particles the mol-
ten lipid/ API formula can be sprayed into a cooling chamber [128]. The
so-called spray cooling or spray congealing technique uses the same
lipids as hot-melt technology. Lipid particles produced in this way
may be used for tableting to produce for example controlled release
dosage forms [129]. One key parameter that needs to be considered is
the API load of the formulations, as this inﬂuences the viscosity of the
spray liquid, since dispersions generally tend to be more viscous than
solutions. So far a maximum of 30% drug load has been reported
[130]. Larger spherical pellets can be obtained using a similar process
whereby a melted suspension is dropped onto a cooled surface [131].
Hot or cold extrusion offers the advantage to apply taste masking to
APIs which are sensitive to moisture and in the case of cold extrusion,
those sensitive to heat. Both technologies can be combined with a
spheronization process to produce pellets. Lipid pellets representmulti-
ple unit (often sustained release) matrix dosage forms that combineseveral advantages. As stated previously, multiple unit dosage forms
are easy to swallow, and also possess more reproducible gastrointesti-
nal transit times compared to monolithic dosage forms and so there is
a lower risk for dose dumping [132].
Another technique for lipid-based taste masking is the preparation
of solid lipid nanoparticles (SLN). However, SLN are generally utilised
as a drug carrier system rather than a tastemasking opportunity. Classic
components of SLN are glyceryl dibehenate as the solid matrix and
poloxamers or polysorbates as surfactants. SLN can be produced
through hot or cold high pressure homogenization. For both techniques
the drug is dissolved or solubilized in the molten lipid. Afterwards it is
either dispersed in a hot surfactant solution and homogenized or it is
cooled, ground and then dispersed in cold surfactant solution and
then homogenized [133].
6.2.1. Commonly used lipidic excipients for taste masking
Lipids are naturally occurring compounds that are predominantly
digestible and have GRAS status and therefore offer an advantage for
use in paediatric formulations. Lipids commonly used for coating are
glycerides, i.e. esters of glycerol and fatty acids and depending on the
nature of the fatty acid and their degree of esteriﬁcation, they are
more or less digestible by lipases [134].
Themain lipid excipients that are used in the pharmaceutical indus-
try together with their ADI limits are provided in Table 12, including
vegetable oil derivatives such as hydrogenated vegetable oils, partial
glycerides, polyoxylglycerides, ethoxylated glycerides and esters of edi-
ble fatty acids and various alcohols (waxes). The common components
are fatty acids.
6.2.2. Formulations containing lipidic excipients for taste masking
Examples of formulations that may be suitable for children where
lipid excipients have been used for taste masking are provided in
Table 13 and discussed below.
Chewable taste masked tablets containing bitter tasting acetamino-
phen (paracetamol) have been developed by Suzuki et al. [135,136]. A
mixture of Witepsol H-15, (hydrogenated coco-glycerides, a hard fat),
Benecoat BMI-40, (a commercial bitter-masking powder mixture
made from lecithin), and sucrose was found to have the best taste
masking properties without inﬂuencing the desired immediate release
proﬁle. The mouthfeel could be further improved by using Witocan H,
(triglycerides based on coconut/palm kernel oil) instead, but the
addition of the Benecoat BMI-40 bitterness suppressant was needed.
As previously mentioned in Section 6.1, solid lipid extrusion with mix-
tures of hard fat (hydrogenated coco-glycerides) and PVA-PEG graft
copolymer has been described as being successful for taste masking
the poorly soluble model API NXP120 [108].
Paracetamol has also been successfully taste masked by hot melt
coating using different combinations of lipids (for example Precirol®
(glyceryl distearate) and Sterotex® HM (hydrogenated soybean oil))
with emulsiﬁers and disintegrants to improve dissolution [137,138].
Further examples of drugs that have been successfully taste masked
using a hot melt coating technique include chloroquine and theophyl-
line, using glyceryl dibehenate [132,139] and bromhexine hydrochlo-
ride and salbutamol sulphate using bees wax and cetyl alcohol [140].
In the latter, complete in vivo taste masking was achieved using a coat-
ing level of 5% w/w. Microparticles of indeloxazine hydrochloride have
been successfully tastemasked using a coating of a mixture of hydroge-
nated oil and surfactants [141].
The bitter and salty tasting drug sodium benzoate could be masked
by producing pelletswith hard fat (Witocan 42/44), glyceryl dibehenate
(Compritol® 888 ATO), glyceryl trimyristate (Dynasan 114) and glycer-
yl distearate (Precirol ATO5®). The obtained pellets, evaluated via a
human taste panel and electronic tongue, had a better taste masking
ability than saliva-resistant coated granules [142]. Although carnauba
wax has been used to prepare delayed-release dosage forms [126], it
may also confer taste masking properties to the API or product. It is
Table 12
Toxicity data on commonly used lipids for taste masking.
Excipient name Brand name Pharmacopoeia Comment
Hydrogenated vegetable oils
Hydrogenated cottonseed oil Lubritab™ ADI: not established
Hydrogenated palm oil Dynasan™ P60, Softisan™ 154 USP-NF: not listed ADI: not established
Partial glycerides
Glyceryl monostearate (GMS) Imwitor® 191, Cutina™ GMS or Tegin™ USP-NF ADI: not limited
Glyceryl distearate Precirol® ATO 5 USP-NF, PhEur ADI: not limited
Glyceryl dibehenate Compritol® 888 ATO USP-NF, PhEur ADI: not limited
Triglycerides (TAG)
Glyceryl trimyristate Dynasan® 114 Not listed ADI: Not limited
LD50 oral (rat) all types N 5 g/kg bwGlyceryl tristearate Dynasan® 118 21 CFR §172.811 JCIC
Polyoxyglycerides or macrogolglycerides
Lauroyl polyoxylglycerides Gelucire® 44/14 USP-NF, PhEur LD50 oral (rat) N 20 g/kg
Stearoyl polyoxylglycerides Gelucire® 50/13 USP-NF, PhEur LD50 oral (rat) N 20 g/kg
Waxes/hard fat
Carnauba wax – USP-NF, PhEur ADI: 7.0 mg/kg bw
LD50 not established
Bees wax – USP-NF, PhEur ADI: acceptable
Polyethylene glycol (PEG)a Carbowax®; Macrogol 1500 USP-NF, PhEur ADI: 10.0 mg/kg bw
LD50 oral (rat) N 15 g/kg
Hydrogenated coco-glycerides Witepsol W35 USP-NF, PhEur, JP, DMF LD50 oral (rat) N 2 g/kg
Witocan 42/44 USP-NF, PhEur
USP-NF — United States Pharmacopoeia National Formulary, PhEur— European Pharmacopoeia, JP — Japanese Pharmacopoeia, DMF — Drug Master File.
Source of toxicity data: Joint Expert Committee on Food Additives (JECFA).
a PEG in molecular weights of 1500 and 6000 is chemically not a wax but has been included due to their use as excipient for e.gn solid lipid extrusion.
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ple Kalydeco™ and Colcrys® tablets.
Solid lipid extrudateswith the bitter drug praziquantel are described
by Witzleb et al. [143]. The taste of extrudates with diameter down to
0.2mm, a drug loadup to 70% and addition of up to 20% PEGwere tested
in a palatability study in cats. Since cats react very sensitively to bitter
taste and generally reject food that is given togetherwith a bitter tasting
medicine this study suggests that there would also be sufﬁcient taste
masking for humans.
Lipid extrudates containing praziquantel or enroﬂoxacin with taste
masking properties were investigated by Michalk et al. [144] using
glyceryl dibehenate as the lipid component. The tastemaskingwas indi-
rectly measured by a special short time dissolution test. The release
from the extrudates at pH 7.4 was low and increased with increasing
diameter of extrudates.
These studies demonstrate that salty or bitter tasting APIs can be
efﬁciently taste masked using lipids or combinations of different
lipids alone or mixed with other excipients. The obtained granules,
pellets or microspheres are already considered as age-appropriate
dosage forms and offer the possibility to process them further into
other child-friendly dosage forms. Due to the advantage of low safety
concerns or ADI restrictions, lipids are an interesting and promising
class of excipients for taste masking. However, effect on API bioavail-
ability and the inﬂuence of storage (especially under accelerated
conditions) on physico-chemical properties, need to be studied
further.Table 13
Lipid excipients used for taste masking of formulations suitable for children.
Excipient name Drug
Glyceryl distearate; hydrogenated soybean oil Paracetamo
Glycerol trimyristate; glyceryl dibehenate; glyceryl distearate; hard fat Sodium be
Hydrogenated coco-glycerides NXP120
Acetamino
Glycerol tristrearate Praziquant
Glyceryl dibehenate Theophyllin
Praziquant
Bees wax, cetyl alcohol Bromhexin
Salbutamol7. Summary and conclusions
The taste of an oral paediatric product can have a huge impact on its
acceptability and acceptable palatability is of great importance for
paediatric medicinal products to facilitate patient adherence. The devel-
opment of palatable oral dosage forms for children is challenging [145];
many APIs have an unpleasant taste, and so it is necessary to obscure or
mask this propertywithin the formulation.When developingmedicines
for children, the selection of suitable age-appropriate dosage form for
the proposed paediatric population should be based on a beneﬁt risk
approach, taking into account safety, efﬁcacy/ease of use and patient
access [146]. Part of this process should consider the need for taste
masking. Choice of taste masking technique should take into account
the organoleptic properties of the API, in addition to its physico-
chemical properties.
This review has provided an overview of different approaches that
may be applied for the tastemasking of APIs in oral paediatricmedicinal
products, with a focus on the excipients used. Fig. 4 proposes a tool/
framework to help to summarise all the aforementioned reﬂection on
taste masking approaches to age appropriate formulations. This is not
intended to be a guidance as such butmore a rational/practical proposal
that may be applied during development.
More than one taste masking technique may be used, and each has
advantages and disadvantages. In general, the use of sweeteners and
ﬂavours is often the ﬁrst approach investigated. This is because a wide
range of sweeteners and ﬂavouring agents are available, specialDosage form Paediatric use Reference
l Granules – [137]
nzoate Pellets ✔ [142]
Pellets – [108]
phen Chewable tablet – [135,136]
el Pellets – [143]
e; Chloroquine Granulates – [132,139]
el, Enroﬂoxacin Pellets – [144]
e HCl Pellets – [140]
Children >2-5 yrsChildren 1-5 yrs
Dose flexibility required?
Acceptable API taste?
NoYes
Yes
Soluble?
Yes NoNo
Yes No
Dosing with or without food
or drink
Chewable 
tablet
Orally 
disintegrating 
or dispersible 
tablet 
Film coated 
tablet or 
capsule
Film coated 
sprinkles (mini-
tablets, granules, 
pellets)
Consideration of bioperformance
Agree target product profile 
Acceptable API taste?
Solution Suspension
API taste threshold?
Coating technologies for  taste masking
Neonates
Stability will influence whether 
RTU* solution/suspension or 
powder for reconstitution
developed
Fig. 4. Taste masking approaches for age-appropriate formulations.
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lease rates are unlikely to be affected. Despite these advantages, the use
of sweeteners and ﬂavours is not the most effective means of taste
masking and selection of sweeteners and ﬂavours. Modiﬁcation of an
APIs solubility may improve its taste characteristics, although this
approach is not suitable for all APIs and would often be used in combi-
nation with sweetener/ﬂavour. Furthermore, potential effects on PK
characteristics need to be considered.
The use of complexation with IERs or CDs is likely to be more effec-
tive than the use of ﬂavours and sweeteners, although it is more techni-
cally challenging. Indeed, the suitability of complexation for taste
masking depends upon the physico-chemical properties of the API and
the dose required. Polymeric and lipidic coatings are considered to be
the most effective techniques for taste masking. However, as for com-
plexation, these approaches are more technically challenging than the
use of ﬂavours and sweeteners alone and specialist equipment may be
required. In addition, coatingsmay have an impact on the bioavailability
of the paediatric product.
Bitter blockers and taste modiﬁers offer an interesting alternative
approach to taste masking. The use of these compounds is fairly new
and unproven.
It can therefore be concluded that a range of techniquesmay be used
for the tastemasking of paediatric medicinal products. Selection of taste
masking approach needs to be done on a case-by-case basis.
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